patent/ES-2884674-T3

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2884674-T3

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88a67609a75d1eed8a59a4025944c0ef
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-243 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-555 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-243
filingDate	2009-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate	2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_750d74909866e32de2a848138e7c5a17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0ab3256dded2b098ab1138eb9820a351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_97504ced8ddab8b1ca0370746c2c979c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3157a18a385928483f181dbd624b254 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7600dd5125cc20e3edd25c259667a9ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e6860b463c23794b9b1d76586e20211
publicationDate	2021-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	ES-2884674-T3
titleOfInvention	Cancer treatment with the hypoxia-activated prodrug TH-302 in combination with docetaxel or pemetrexed
abstract	Compositions for use in a method of treating lung cancer, wherein the first composition comprises (1-methyl-2-nitro-1H-imidazol-5-yl) N,N'-bis(2- bromoethyl) phosphoroidal (TH-302) and the second composition comprises docetaxel, wherein an effective dose of TH-302 is administered first, followed by administration of a therapeutically effective dose of docetaxel 2 to 24 hours after the end of the administration of TH-302.
priorityDate	2008-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163522703 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465101862

Total number of triples: 53.